David P. King elected to Illumina's Board of Directors. PR Newswire Today at 1:15pm PDT Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ - Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care. "We are delighted to welcome David to the Illumina Board," said Jacob Thaysen, chief executive officer of Illumina. "David brings deep regulatory knowledge, broad industry credibility, and the respect earned over decades at the forefront of healthcare and life sciences. Under his leadership at Labcorp, the company tripled in size through organic growth and strategic acquisitions. His perspective across diagnostics, healthcare delivery, and board governance will strengthen our ability to deliver long-term impact for patients, customers, and shareholders." Mr. King is the former Executive Chairman and Chief Executive Officer of Labcorp. Under his leadership, Labcorp entered the Fortune 500, and was recognized by Fortune as one of the World's Most Admired Companies. Mr. King joins the Board following the retirement of Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, each of whom concluded distinguished tenures on the Board at the company's annual meeting. About David P. King David P. King was elected to Illumina's Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth. Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022-2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland. Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School. About Illumina Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established Oregon Capital Insider as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with Oregon Capital Insider on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Investors: Illumina Investor Relations 858-291-6421 [email protected] SOURCE Illumina, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.

Mitalab officially becomes A comprehensive distribution partner of Illumina. Dear Valued Partners and Customers, Mitalab is honored to announce a significant strategic milestone in its collaboration journey. Effective from May 13, 2026, Mitalab has officially become the comprehensive distributor of both Illumina's "IVD Diagnostics" and "RUO Research" product portfolios. Illumina is globally recognized as a leading innovator in genomic sequencing and biotechnology. Becoming an authorized distributor for both the IVD and RUO product lines not only marks a major advancement in the partnership between Mitalab and Illumina, but also demonstrates Mitalab's professional expertise, operational capability, and strong reputation in the healthcare and life sciences sector. Mitalab is committed to delivering a comprehensive Next-Generation Sequencing (NGS) ecosystem that simultaneously supports clinical applications, enhances diagnostic and treatment efficiency, and advances in-depth scientific research. As modern medicine and genomic technologies continue to play an increasingly vital role in healthcare, Mitalab's access to Illumina's advanced platforms will create new opportunities to improve the quality of medical diagnosis, laboratory services, and scientific research for hospitals, laboratories, research institutes, and the scientific community across Vietnam. This milestone is not only a source of pride for Mitalab, but also a strong motivation for Mitalabvn to continuously update and deliver cutting-edge medical technologies, contributing to the advancement of diagnostics, scientific innovation, and community healthcare. Once again, congratulations on this remarkable and meaningful partnership milestone.